Candesartan cilexetil
Candesartan cilexetil structure
|
Common Name | Candesartan cilexetil | ||
|---|---|---|---|---|
| CAS Number | 145040-37-5 | Molecular Weight | 610.660 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 843.3±75.0 °C at 760 mmHg | |
| Molecular Formula | C33H34N6O6 | Melting Point | 168-170?C | |
| MSDS | Chinese USA | Flash Point | 463.8±37.1 °C | |
| Symbol |
GHS08, GHS09 |
Signal Word | Warning | |
|
Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
AAPS PharmSciTech 16(1) , 108-17, (2015) The aim of this study was to prepare candesartan cilexetil-loaded niosomes and mixed niosomes to enhance the aqueous solubility of the drug, thus improving its oral bioavailability. The formulations were prepared using various types and combinations of surfac... |
|
|
Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan.
Acta. Pharm. 64(4) , 463-74, (2014) Available tablets or capsules for adults are often used to prepare extemporaneously formulated medicines appropriate for children. The most acceptable drug forms in pediatric population are oral liquids and pharmacists use commercial dispersing media to compo... |
|
|
Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
Drug Metab. Dispos. 42(9) , 1522-31, (2014) Hydrolysis plays an important role in metabolic activation of prodrugs. In the current study, species and in vitro system differences in hepatic and extrahepatic hydrolysis were investigated for 11 prodrugs. Ten prodrugs in the data set are predominantly hydr... |
|
|
The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.
Biochim. Biophys. Acta 1838(10) , 2439-50, (2014) ΑΤ1 receptor (AT1R) antagonists exert their antihypertensive effects by preventing the vasoconstrictive hormone AngII to bind to the AT1 receptor. It has been proposed that these biological effects are mediated through a two-step mechanism reaction. In the fi... |
|
|
Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
J. Renin Angiotensin Aldosterone Syst. 4(2) , 96-9, (2003) Blood pressure (BP) reduction is the key to risk reduction of cardiovascular disease or renal failure in hypertensive patients with diabetes mellitus. Inhibition of the renin-angiotensin system by an angiotensin-converting enzyme (ACE) inhibitor or an angiote... |
|
|
CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.
PLoS ONE 10 , e0133616, (2015) Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiov... |
|
|
Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke.
Neurobiol. Dis. 71 , 292-304, (2014) Pressor response after stroke commonly leads to early death or susceptibility to stroke recurrence, and detailed mechanisms are still lacking. We assessed the hypothesis that the renin-angiotensin system contributes to pressor response after stroke by differe... |
|
|
Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Drugs 62(5) , 787-816, (2002) The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension. The blood pressure (BP) lowering effect of various do... |
|
|
Candesartan cilexetil: a review of its use in the management of chronic heart failure.
Drugs 65(4) , 537-58, (2005) Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of ... |
|
|
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
Curr. Med. Res. Opin. 23(7) , 1693-705, (2007) Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) ... |